 Activation of peptide prodrugs by hK2 |
| What is claimed is: 1. A composition comprising a prodrug, the prodrug comprising a therapeutically ... |
|
| Device having diarrhea diagnostic panel |
| The present invention is directed to a device that comprises a sensor adapted to detect one or more ... |
|
| Method for the treatment of chemonucleolysis |
| A method of this invention involves a treatment comprising administering to a mammal in need of ... |
|
| Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| The present invention provides such monoclonal antibodies, HB22, which identify a region of the CD22... |
|
| PRO1312 polypeptides |
| 1. PR0281 A cDNA clone (DNA16422-1209) has been identified, having homology to nucleic acid ... |
|
| Purified p75 (type II) tumor necrosis factor receptor polypeptides |
| The present invention provides isolated TNF receptors and DNA sequences encoding mammalian tumor ... |
|
| Derivatives of choline binding proteins for vaccines |
| OF THE INVENTION In accordance with an aspect of the present invention there is provided a vaccine ... |
|
| Pneumococcal protein homologs and fragments for vaccines |
| OF THE INVENTION The present invention is directed to novel polynucleotides and polypeptides ... |
|
| Bv8 nucleic acids and polypeptides with mitogenic activity |
| The present invention is based on the identification of novel activities of Bv8. In particular, Bv8 ... |
|
| Four genetic tumor markers specific for human glioblastoma |
| We claim: 1. A method of specifically delivering a reagent to a glioblastoma, comprising the step ... |
|
|
Compositions structured with at least one polymer and methods of using the same
| Details |
Inventors: Ferrari, Ve; Simon, Pascal;
Assignee: L'Oreal S.A. (Paris, FR)
Primary Examiner: Venkat; Jyothsna
Assistant Examiner:
Attorney, Agent or Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
A structured cosmetic composition and process of structuring a cosmetic composition comprising at least one amphiphilic compound, at least one dyestuff, and at least one continuous liquid fatty phase structured with a sufficient amount of at least one structuring polymer, wherein the structured composition is in the form of a non-migrating and wax-free solid and wherein the at least continuous liquid fatty phase, the at least one structuring polymer, the at least one amphiphilic compound, and the at least one dyestuff form a physiologically acceptable medium. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A structured cosmetic composition comprising: (i) at least one continuous liquid fatty phase, wherein said at least one continuous liquid fatty phase is structured with a sufficient amount of at least one polymer of formula (I) and mixtures thereof: ##STR00002## in which: n is an integer which represents the number of amide units such that the number of ester groups present in said at least one structuring polymer ranges from 10% to 50% of the total number of all said ester groups and all said amide groups comprised in said at least one structuring polymer; R.
sup.
1, which are identical or different, are each chosen from alkyl groups comprising at least 4 carbon atoms and alkenyl groups comprising at least 4 carbon atoms; R.
sup.
2, which are identical or different, are each chosen from C.
sub.
4 to C.
sub.
42 hydrocarbon-based groups with the proviso that at least 50% of R.
sup.
2 are chosen from C.
sub.
30 to C.
sub.
42 hydrocarbon-based groups; R.
sup.
3, which are identical or different, are each chosen from organic groups comprising atoms chosen from carbon atoms, hydrogen atoms, oxygen atoms and nitrogen atoms with the proviso that R.
sup.
3 comprises at least 2 carbon atoms; and R.
sup.
4, which are identical or different, are each chosen from hydrogen atoms, C.
sub.
1 to C.
sub.
10 alkyl groups and a direct bond to group chosen from R.
sup.
3 and another R.
sup.
4 such that when said at least one group is chosen from another R.
sup.
4, the nitrogen atom to which both R.
sup.
3 and R.
sup.
4 are bonded forms part of a heterocyclic structure defined in part by R.
sup.
4--N--R.
sup.
3, with the proviso that at least 50% of all R.
sup.
4 are chosen from hydrogen atoms; (ii) at least one amphiphilic compound chosen from amphiphilic compounds which are liquid at room temperature and have an HLB value of less than 12; and (iii) at least one dyestuff, wherein said structured composition is in the form of a non-migrating, wax-free solid, and wherein said at least one continuous liquid fatty phase, said at least one polymer, said at least one amphiphilic compound, and said at least one dyestuff form a physiologically acceptable medium
|
| Related patents |
|
|
Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
OF THE INVENTION The invention provides for peptides derived from a neutrophil bacterial permeability protein (B/PI). The peptides are those that are biologically ...
|
|
|
Therapeutic uses of bactericidal/permeability-increasing protein dimer products
The present invention provides significant improvements in therapeutic uses of BPI protein products through the provision of product formulations which include BPI ...
|
|
|
Synthesis of soluble .beta.-sheet forming peptides
OF THE INVENTION An intricate interplay exists between peptide .beta.-sheet formation, self-association, and water solubility. A challenge in making a soluble folded ...
|
|
|
Flavivirus antigen
What is claimed is: 1. An antigen consisting essentially of an amino acid sequence represented by the following formula (I): Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe I...
|
|
|
Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
OF THE INVENTION The present invention provides poxvirus containing formulation, in particular an aqueous poxvirus containing formulation. The formulation, in ...
|
|
|
Screening method for orthopoxvirus antivirals
What is claimed is: 1. An assay comprising the steps of: infecting cultured cells with vaccinia virus; co-transfecting the cells with one or more plasmids comprising DNA ...
|
|
|
Fibrinogen receptor antagonists
OF THE INVENTION Compounds of the invention are fibrinogen receptor antagonists which inhibit fibrinogen induced platelet aggregation. These compounds are prepared by ...
|
|
|
Cyclic peptides containing Arg-Gly-Asp, and derivatives thereof, as adhesion inhibitors
We claim: 1. A cyclopeptide compound of formula I cyclo-(Arg-B-Asp-D-E) I, wherein: B is Gly, Ala, or--HN--Q--CO--; D is Phe, 4-Hal-Phe, Nal, or Phig; E is Gly, Ala, Lys,...
|
|
|
Platelet aggregation inhibitors
We claim: 1. A method of treating or preventing a platelet associated ischemic disorder in a patient comprising administering to said patient an effective amount of a ...
|
|
|
Adhesion receptor antagonists
What is claimed is: 1. An oxazolidinone compound of formula I ##STR10## wherein R.sup.1 is ##STR11## R.sup.2 is H, A, Ac, A--SO.sub.2 --, Ar--SO.sub.2 -- or the amino ...
|
|
|
Drugs 
